Compare · LJPC vs NBIX
LJPC vs NBIX
Side-by-side comparison of La Jolla Pharmaceutical Company (LJPC) and Neurocrine Biosciences Inc. (NBIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LJPC and NBIX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- NBIX carries a market cap of $16.94B.
- NBIX has hit the wire 11 times in the past 4 weeks while LJPC has been quiet.
- NBIX has more recent analyst coverage (25 ratings vs 0 for LJPC).
- Company
- La Jolla Pharmaceutical Company
- Neurocrine Biosciences Inc.
- Price
- -
- -
- Market cap
- -
- $16.94B
- 1M return
- -
- +22.15%
- 1Y return
- -
- +16.48%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1994
- 1996
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 25
La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company was incorporated in 1989 and is headquartered in San Diego, California.
Neurocrine Biosciences Inc.
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Â Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Latest LJPC
- SEC Form 15-12G filed by La Jolla Pharmaceutical Company
- SEC Form SC 13D/A filed by La Jolla Pharmaceutical Company (Amendment)
- SEC Form SC 13D filed by La Jolla Pharmaceutical Company
- SEC Form 4 filed by Rosen Robert
- SEC Form 4: Ramsay David A returned $623,000 worth of shares to the company (100,000 units at $6.23), closing all direct ownership in the company
- SEC Form 4 filed by Tang Kevin C
- SEC Form 4: Edwards Larry G. returned $74,567 worth of shares to the company (11,969 units at $6.23), closing all direct ownership in the company
- SEC Form 4 filed by Hearne Michael S
- SEC Form 4: Johnson Laura L. returned $3,115 worth of shares to the company (500 units at $6.23), closing all direct ownership in the company
- SEC Form 4: Johnson Craig A returned $74,760 worth of shares to the company (12,000 units at $6.23), closing all direct ownership in the company
Latest NBIX
- Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
- Chief Medical Officer Roberts Eiry was granted 8,314 stock options and was granted 1,506 restricted stock units (SEC Form 4)
- Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules
- Director Morrow George J exercised 15,000 shares at a strike of $53.64 and sold $2,335,982 worth of shares (15,000 units at $155.73) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Gano Kyle converted options into 614 shares and covered exercise/tax liability with 332 shares, increasing direct ownership by 0.18% to 155,010 units (SEC Form 4) to satisfy withholding obligation
- Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress
- Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
- SEC Form 10-Q filed by Neurocrine Biosciences Inc.
- Neurocrine Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia